期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
ET2周与3周方案在局部进展期乳腺癌新辅助治疗中的应用对比观察 被引量:1
1
作者 阚士锋 贾锋 《现代肿瘤医学》 CAS 2007年第9期1285-1287,共3页
目的:观察对比表阿霉素联合泰索帝(ET)2周与3周化疗方案术前治疗局部进展期乳腺癌(LABC)的总有效率、病理完全缓解率、保乳率、术前等候时间以及毒副反应。方法:共有90例患者入组,随机分为ET2周组(N=48例)和ET3周组(N=42例)。... 目的:观察对比表阿霉素联合泰索帝(ET)2周与3周化疗方案术前治疗局部进展期乳腺癌(LABC)的总有效率、病理完全缓解率、保乳率、术前等候时间以及毒副反应。方法:共有90例患者入组,随机分为ET2周组(N=48例)和ET3周组(N=42例)。ET2周组治疗方案为:表阿霉素40mg/m2,静脉滴注,d1,2;泰索帝60mg/m2,静脉滴注1小时,d3;2周为1周期,共化疗3周期;ET3周组方案用药不变,以3周做为1周期,共化疗3周期。完成3周期新辅助治疗后10-14天行手术或放疗。结果:ET2周组中48例患者病理完全缓解(pCR)6例(12.5%),总有效率(CR+PR)89.6%,14例(29.2%)行保乳手术,术前等待时间52-56天,中位时间53天;ET3周组42例患者:病理完全缓解(pCR)3例(7.1%),总有效率(CR+PR)69.1%,5例(11.9%)行保乳手术,术前等待时间73-77天,中位时间76天。治疗过程中有程度不等的骨髓抑制、胃肠道反应和脱发等毒副反应,两组无1例患者终止治疗,均未发生药物所致的死亡。结论:ET2周密集化疗方案术前治疗局部进展期乳腺癌疗效优于3周常规方案,缩短了术前等待时间,且耐受性好。 展开更多
关键词 乳腺肿瘤/化学治疗 泰索帝 表阿霉素
下载PDF
多西紫杉醇联合卡培他滨治疗晚期乳腺癌的临床观察 被引量:1
2
作者 孙艳丽 陈武 冯立艳 《中国肿瘤临床与康复》 2006年第5期409-412,共4页
目的 观察多西紫杉醇联合卡培他滨治疗蒽环类药物治疗失败复发转移性乳腺癌的近期疗效和不良反应,并与长春瑞滨(NVB)和顺铂(DDP)组成的NP方案进行比较.方法 蒽环类药治疗失败的复发转移性乳腺癌患者,选择匹配68例,分为A(治疗组)和... 目的 观察多西紫杉醇联合卡培他滨治疗蒽环类药物治疗失败复发转移性乳腺癌的近期疗效和不良反应,并与长春瑞滨(NVB)和顺铂(DDP)组成的NP方案进行比较.方法 蒽环类药治疗失败的复发转移性乳腺癌患者,选择匹配68例,分为A(治疗组)和B(对照组)两组. A组32例接受多西紫杉醇联合卡培他滨方案,多西紫杉醇75 mg/m2,静滴,第1天;卡培他滨950 mg/mv2,每日2次口服,第1~14天.B组36例采用NP方案,NVB 25 mg/m^2,第1、8天,静滴;DDP 80 mg/m^2,分3 d(d1~3)静滴,每3周重复一次.治疗2个周期以上评价疗效.结果 68例患者均可行疗效和不良反应评价,A组和B组有效率分别为71.9%(23/32)和44.4%(16/36),两组差异有显著性(P<0.05);中位肿瘤进展时间(TTP)A组和B组分别为5.7个月和3.8个月,差异有显著性(P<0.01).两组主要不良反应均为中性粒细胞减少,A组和B组Ⅲ、Ⅳ度中性粒细胞减少发生率分别为53.1%和44.4%,差异无显著性(P>0.05).A组主要不良反应还有手足综合征,多为Ⅰ~Ⅱ度.结论 多西紫杉醇联合卡培他滨是治疗蒽环类治疗失败复发转移性乳腺癌的有效方案,其有效率优于NP方案,不良反应可以耐受. 展开更多
关键词 乳腺肿瘤/化学治疗 卡培他滨 多西紫杉醇 长春瑞滨 顺铂
下载PDF
Analysis of the Indicence and Survival of Female Breast Cancer Patients in Beijing Over a 20-Year Period
3
作者 Qijun Wang Weixing Zhu Xiumei Xing Chenxu Qu 《Chinese Journal of Clinical Oncology》 CSCD 2006年第6期433-436,共4页
OBJECTIVE To provide evidence for breast cancer prevention and control through epidemiological analysis of the incidence, mortality and survival rate of female breast cancer patients in Beijing. METHODS The female reg... OBJECTIVE To provide evidence for breast cancer prevention and control through epidemiological analysis of the incidence, mortality and survival rate of female breast cancer patients in Beijing. METHODS The female registration data in the Beijing urban area from 1982 to 2001 were retrospectively reviewed. The incidence, mortality and survival rate of female breast cancer patients were analyzed using routine and life-table statistical methods. RESULTS During the period of 1982 to 2001, there was a trend of an average annual increase of female breast cancer incidence of 4.6% in urban Beijing, and of 4,9% in the world-population standardized incidence. The epidemiological features of urban Beijing female breast cancer showed:(1)The incidence distribution of different age groups from 25 to 80 years elevated with two peaks at ages of 45- and 70- years; (2)There was an elevation in each age group over the last 20 years; (3)The incidence rate at ages of 35 to 64 reached 95.3/10^5, causing breast cancer to become the number one cancer in females. The changes in the survival rate showed the following: the 5-year observed survival rate (OSR) increased from 62.0% in 1982~1983 to 68.7% in 1987-1988, and the relative-survival rate (RSR) increased from 6613% to 74.2%. The 10-year OSR and RSR in 1987~1988 were 60.3% and 65.1%, and at 15 years 57.5% and 61.3%, respectively. The mortality rate of breast cancer patients fluctuated from 8 to 10 per 105 population over the 20 years of study. CONCLUSION There is a trend of an annual increase in female breast cancer in Beijing. The 5-year survival is being improved gradually while the mortality remains stable. The results demonstrate that the principles of "early prevention, diagnosis and treatment" for breast cancer are effective in Beijing. 展开更多
关键词 breast neoplasms inddence MORTALITY survival rate
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部